News – Page 1080 – Endpoints News

Indivior tightens grip on opioid addiction market with Sublocade's new FDA approval

8 years ago

Cures Act implementation: Gottlieb says faster cancer drug approvals coming for secondary indications

8 years ago

Senators grill Alex Azar on drug prices; MorphoSys sells rights to Darzalex rival in $120M deal; Serial dealmaker ...

8 years ago

In reorganization, Joerg Moeller gathers all the pharma R&D reins at Bayer as discovery chief exits

8 years ago

Anti-aging startup ResTORbio gets $40M to fuel Phase IIb study

8 years ago

Major deregulation? FDA withdraws several rules and regulations related to medical products

8 years ago

After all the love and money, analysts speculate that J&J may swoop in with a buyout offer for Genmab

8 years ago

Sanofi’s dengue vaccine slams into a safety issue, triggering a $120M write-off and eviscerating old blockbuster ...

8 years ago

J&J-led coalition launches a landmark efficacy study for an HIV mosaic vaccine

8 years ago

Looking to cure Type 1 diabetes, investors front $114M to launch a pioneering human study at Semma

8 years ago

Amgen pulls ahead in sprint towards CGRP approval with promising PhIII migraine data

8 years ago

J&J disputes report it’s dropping JLabs plans for UK; Takeda takes Zika vaccine into PhI

8 years ago

New backers Sofinnova and Scopia bring Y-mAb's round to $80M for anti-cancer drugs

8 years ago

University was tipped off to possible unauthorized trials of herpes vaccine

8 years ago

Bluebird bio orchestrates a series of deals and a buyout to guarantee gene therapy manufacturing

8 years ago

Frazier backs MavuPharma’s $20M round, brings in heavyweight execs to lead

8 years ago

In latest deal, Melinta executes $270M pact to buy out Medicines Co’s infectious disease group

8 years ago

Doug Williams ups the ante at Codiak Bio to $168.5M in a drive to first human study

8 years ago

Regeneron and Decibel aren’t just collaborating: They want to create a whole new partnering model

8 years ago

Vir chief Scangos picks Herbert ‘Skip’ Virgin to run R&D; Ardelyx forges $160M deal with Kyowa Hakko Kirin

8 years ago

RA backs Medeor’s $57M round as researchers fast forward to PhIII

8 years ago

Pharma's broken business model: An industry on the brink of terminal decline

8 years ago

Pfizer, Merck KGaA run into a severe setback as PD-L1 drug Bavencio fails in PhIII gastric cancer study

8 years ago

Strike two: Auris shares crushed again as its second PhIII program fails to deliver

8 years ago

First page Previous page 1077 1078 107910801081 1082 1083 Next page Last page